Overview

First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors

Status:
Recruiting

Trial end date:
2024-05-27

Target enrollment:

Participant gender:

Summary

The purpose of this study will be to determine the Maximum Tolerated Dose (MTD) and describe dose-limiting toxicities (DLTs) of W0180 given as monotherapy and in combination with pembrolizumab (anti-PD-1).

Phase:

Phase 1

Details

Lead Sponsor:

Pierre Fabre Medicament

Treatments:

Pembrolizumab